4 research outputs found
Estudio del tratamiento quirúrgico del cáncer gástrico.
241 p.El cáncer gástrico es la quinta neoplasia más frecuente en el mundo y la tercera causa más frecuente de mortalidad por tumor en varones en el mundo. Su tratamiento comprende desde una resección endoscópica hasta una cirugía complementada con quimioterapia o radioterapia.En esta tesis se estudia a los pacientes con cáncer gástrico tratados en el servicio de cirugía esofagogástrica del Hospital Universitario Donostia durante 13 años (2003-2016), siendo el objetivo principal de la misma demostrar la hipótesis de que en este periodo de tiempo se ha mejorado la supervivencia de estos pacientes.Para ello, se analizan las características demográficas de los pacientes, la localización tumoral en el estómago, las diferentes técnicas quirúrgicas, las complicaciones postoperatorias, la anatomía patológica del tumor, los diferentes tratamientos complementarios, la mortalidad postoperatoria, la supervivencia libre de enfermedad y la supervivencia global entre otras variables.Se concluye que, efectivamente, ha habido un aumento de la supervivencia de los pacientes con cáncer gástrico tratados con cirugía en este periodo de tiempo
Estudio del tratamiento quirúrgico del cáncer gástrico.
241 p.El cáncer gástrico es la quinta neoplasia más frecuente en el mundo y la tercera causa más frecuente de mortalidad por tumor en varones en el mundo. Su tratamiento comprende desde una resección endoscópica hasta una cirugía complementada con quimioterapia o radioterapia.En esta tesis se estudia a los pacientes con cáncer gástrico tratados en el servicio de cirugía esofagogástrica del Hospital Universitario Donostia durante 13 años (2003-2016), siendo el objetivo principal de la misma demostrar la hipótesis de que en este periodo de tiempo se ha mejorado la supervivencia de estos pacientes.Para ello, se analizan las características demográficas de los pacientes, la localización tumoral en el estómago, las diferentes técnicas quirúrgicas, las complicaciones postoperatorias, la anatomía patológica del tumor, los diferentes tratamientos complementarios, la mortalidad postoperatoria, la supervivencia libre de enfermedad y la supervivencia global entre otras variables.Se concluye que, efectivamente, ha habido un aumento de la supervivencia de los pacientes con cáncer gástrico tratados con cirugía en este periodo de tiempo
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
[EN]Objective Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD.
Design RIPK3 levels were evaluated in two large independent cohorts of patients with biopsy proven NAFLD diagnosis and correlated with clinical and biochemical parameters. Wild-type (WT) or Ripk3-deficient (Ripk3(-/-)) mice were fed a choline-deficient L-amino acid-defined diet (CDAA) or an isocaloric control diet for 32 and 66 weeks.
Results RIPK3 increased in patients with non-alcoholic steatohepatitis (NASH) in both cohorts, correlating with hepatic inflammation and fibrosis. Accordingly, Ripk3 deficiency ameliorated CDAA-induced inflammation and fibrosis in mice at both 32 and 66 weeks. WT mice on the CDAA diet for 66 weeks developed preneoplastic nodules and displayed increased hepatocellular proliferation, which were reduced in Ripk3(-/-) mice. Furthermore, Ripk3 deficiency hampered tumourigenesis. Intriguingly, Ripk3(-/-) mice displayed increased body weight gain, while lipidomics showed that deletion of Ripk3 shifted hepatic lipid profiles. Peroxisome proliferator-activated receptor. (PPAR.) was increased in Ripk3(-/-) mice and negatively correlated with hepatic RIPK3 in patients with NAFLD. Mechanistic studies established a functional link between RIPK3 and PPAR. in controlling fat deposition and fibrosis.
Conclusion Hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. Targeting RIPK3 and its intricate signalling arises as a novel promising approach to treat NASH and arrest disease progression.Main funding is provided by FEDER funds through the COMPETE programme and by national funds through Fundacao para a Ciencia e a Tecnologia to CMPR (grants SAICTPAC/0019/2015-LISBOA-01-0145--FEDER-016405 and PTDC/MED-FAR/29097/2017 -LISBOA-01-0145-FEDER-029097). Additional funding comes from research grant APEF (Portuguese Association for the Study of Liver)/BAYER 2020 to MBA. JG is funded by the Fondation pour la Recherche Medicale (ARF20170938613), the Institute of Cardiometabolism and Nutrition (PAP17NECJG), the Societe Francophone du Diabete (R19114DD) and the Mairie de Paris (Emergences -R18139DD). MBA, PMR, MMP and ALS were investigators or students funded by Fundacao para a Ciencia e a Tecnologia
Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease where liver biopsy remains the gold standard for diagnosis. Here we aimed
to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor
1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with
the metabolome.
Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured
by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and
healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD,
31 controls) and correlated with clinical data, histology, genetic parameters, and
serum metabolomics.
Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC
0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between
obese and non-obese healthy controls, suggesting that obesity is not a confounding
factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis
(NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation
cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC
0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay
performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized
ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).
Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with
specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.CR was funded by FEDER through the COMPETE program
and by national funds through Fundação para a Ciência
e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01-
0145-FEDER-029097) and by European Horizon 2020 (H2020-
MSCA-RISE-2016-734719). This work was also supported by
Fundação para a Ciência e Tecnologia (PD/BD/135467/2017)
and Portuguese Association for the Study of Liver/MSD
2017. JB was funded by Spanish Carlos III Health Institute
(ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program
CON14/00129 and CPII19/00008), co-financed by Fondo
Europeo de Desarrollo Regional (FEDER), Instituto de Salud
Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation
(HR17-00601), Fundación Científica de la Asociación Española
Contra el Cáncer, and European Horizon 2020 (ESCALON
project: H2020-SC1-BHC-2018-2020)